Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tau PET Outcomes in Anti-amyloid Immunotherapies for Alzheimer's Disease
NCT06723015Phase 2Enrolling by invitation
- Sponsor
- Mayo Clinic
- Start
- Nov 2025
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial in Alzheimer's disease (AD) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Change in tau PET Standardized Uptake Value (SUVR) at 18 months. Started Nov 2025; status: enrolling by invitation.
02
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06723015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06723015.